FROM YAHOO NEWS Latest news, live updates as 2024 election results loom Toronto - Delayed Quote ? CAD Theratechnologies Inc. (TH.TO) Follow Compare 1.7800 +0.0900 (+5.33%) At close: November 5 at 3:59 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV Data Show Tesamorelin May Reduce CVD Risk by Reducing EVAFMONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced data from two poster presentations, focusing on the association between excess visceral abdominal fat (EVAF) and cardiovascular disease (CVD) risk in people with HIV (PWH), and on the use of tesam GlobeNewswire ? 19 days ago THTX Theratechnologies Unveils Study Design of PROMISE-US Trial of Ibalizumab Theratechnologies Unveils Study Design of PROMISE-US Trial of Ibalizumab PREMIUM MT Newswires ? 19 days ago THTX Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other RegimensMONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today disclosed the study design and baseline characteristics of participants in the Prospective Observational Study of Multidrug GlobeNewswire ? 19 days ago THTX Theratechnologies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag Theratechnologies ( TSE:TH ) Third Quarter 2024 Results Key Financial Results Revenue: US$22.6m (up 8.4% from 3Q 2023... Simply Wall St. ? 25 days ago THTX Theratechnologies Inc (THTX) Q3 2024 Earnings Call Highlights: Strong Profitability Amid ... Theratechnologies Inc (THTX) reports robust earnings with a net profit of $3 million, despite facing supply constraints and competitive pressures. GuruFocus.com ? 25 days ago THTX Theratechnologies Up 12% in U.S. Premarket Trading After Reporting Q3 Swing to Profit Theratechnologies Up 12% in U.S. Premarket Trading After Reporting Q3 Swing to Profit PREMIUM MT Newswires ? 26 days ago THTX Theratechnologies: Fiscal Q3 Earnings Snapshot MONTREAL (AP) — Theratechnologies Inc. THTX) on Thursday reported earnings of $3.1 million in its fiscal third quarter. The Montreal-based company said it had profit of 6 cents per share. Associated Press Finance ? 26 days ago THTX Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024 Q3 revenue of $22.6 million represents +8% growth year-over-yearPositive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million Fiscal 2024 guidance revised to between $83 and $85 million in revenue and Adjusted EBITDA guidance increased to a range of $17 to $19 million MONTREAL, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerc GlobeNewswire ? 26 days ago THTX Theratechnologies to Present Data Next Week Highlighting Advances in Treatment in People with HIV Theratechnologies to Present Data Next Week Highlighting Advances in Treatment in People with HIV PREMIUM MT Newswires ? 27 days ago THTX Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced three upcoming poster presentations at IDWeek 2024, taking place October 16-19 in Los Angeles, Calif. One poster presents data linking excess visceral abdominal fat (EVAF) to increased cardiovascular risk in people with HIV, while a second poster documen GlobeNewswire ? 27 days ago THTX Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update MONTREAL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2024, on Thursday, October 10 at 8:30 a.m. ET. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. He will be GlobeNewswire ? last month THTX Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays On Tuesday, Theratechnologies Inc. (NASDAQ:THTX) warned of a potential temporary supply disruption of Egrifta SV (tesamorelin for injection) in early 2025. The FDA has approved Egrifta SV as the only treatment for HIV-related excess visceral abdominal fat. The interruption is linked to an unexpected voluntary shutdown of the contract manufacturer’s facility following an FDA inspection. The FDA review timeline could delay the resumption of product distribution, but the company is actively working Benzinga ? last month THTX Theratechnologies Sees Risk of Supply Disruption for Its EGRIFTA SV Drug in Early 2025 Theratechnologies Sees Risk of Supply Disruption for Its EGRIFTA SV Drug in Early 2025 PREMIUM MT Newswires ? last month THTX Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV? in Early 2025 MONTREAL, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary supply disruption for EGRIFTA SV? (tesamorelin for injection) in early 2025 caused by an unexpected voluntary shutdown of the Company’s contract manufacturer’s facility following an inspection by the US Food and Drug Administra GlobeNewswire ? last month THTX Theratechnologies to Present at Upcoming Investor Conferences in September MONTREAL, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul Lévesque will be presenting at two investor conferences in September. Members of the Theratechnologies management team will also be available for one-on-one meetings throughout the conferences. H.C. Wainwri GlobeNewswire ? last month THTX Positive Signs As Multiple Insiders Buy Theratechnologies Stock It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... Simply Wall St. ? 2 months ago THTX Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors Theratechnologies (THTX) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. Zacks ? 3 months ago THTX Theratechnologies Second Quarter 2024 Earnings: Beats Expectations Theratechnologies ( TSE:TH ) Second Quarter 2024 Results Key Financial Results Revenue: US$22.0m (up 26% from 2Q 2023... Simply Wall St. ? 3 months ago THTX Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock Theratechnologies (THTX) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. Zacks ? 3 months ago THTX HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars On Wednesday, Theratechnologies Inc (NASDAQ:THTX) reported second-quarter 2024 sales of $22.02 million, up 25.5% year over year, beating the consensus of $21.71 million. For the second quarter, net sales of EGRIFTA SV were $16.2 million, up 49.3% year over year, due to strong demand for the product, combined with weaker than usual sales in Q2 of last year stemming from drawdowns in inventory early in the second quarter of 2023. EGRIFTA SV is an injectable prescription medicine used to reduce exc Benzinga ? 3 months ago THTX Performance Overview Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return TH.TO S&P/TSX Composite index YTD -16.82% +16.36% 1-Year -1.11% +23.02% 3-Year -89.72% +14.27%
